Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 7/20 | 0.37 |
| ▸ | NPC1 | O15118 | 5/20 | 0.37 |
| ▸ | PLD2 | O14939 | 1/20 | 0.37 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 5/20 | 0.37 |
| ▸ | ADCY1 | Q08828 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16413959 | 0.93 | TRPM8 (0.56) | TRPM8RAB9ANPC1PLD2PLD1 | |
| SCHEMBL16413960 | 0.93 | TRPM8 (0.56) | TRPM8RAB9ANPC1PLD2PLD1 | |
| SCHEMBL15467106 | 0.92 | TRPM8 (0.54) | TRPM8KDM4ERAB9ANPC1PLD2 | |
| SCHEMBL15466808 | 0.92 | TRPM8 (0.54) | TRPM8KDM4ERAB9ANPC1PLD2 | |
| SCHEMBL15467108 | 0.92 | TRPM8 (0.54) | TRPM8KDM4ERAB9ANPC1PLD2 | |
| SCHEMBL15566928 | 0.91 | TRPM8 (0.54) | TRPM8RAB9ANPC1PLD2PLD1 | |
| SCHEMBL15566927 | 0.91 | TRPM8 (0.54) | TRPM8RAB9ANPC1PLD2PLD1 | |
| SCHEMBL15467345 | 0.91 | TRPM8 (0.53) | TRPM8KDM4ERAB9ANPC1DYRK1A | |
| SCHEMBL15467342 | 0.91 | TRPM8 (0.53) | TRPM8KDM4ERAB9ANPC1DYRK1A | |
| SCHEMBL15568816 | 0.90 | TRPM8 (0.52) | TRPM8RAB9APLD2PLD1IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8952009-B2 | Chroman derivatives as TRPM8 inhibitors | AMGEN INC. (US) | 2015-02-10 | — | — | US | disclosed |
| US-20150031668-A1 | CHROMAN DERIVATIVES AS TRPM8 INHIBITORS | AMGEN INC (US) | 2015-01-29 | — | — | US | disclosed |
| US-20140045855-A1 | CHROMAN DERIVATIVES AS TRPM8 INHIBITORS | AMGEN INC. (US) | 2014-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150031668-A1 | CHROMAN DERIVATIVES AS TRPM8 INHIBITORS | TRPM8, TRPM5, TRPM7 | TRPM8 1/4885KDM4E 2769/4885RAB9A 1056/4885 |
| US-20140045855-A1 | CHROMAN DERIVATIVES AS TRPM8 INHIBITORS | TRPM8, TRPM5, TRPM7 | TRPM8 1/4885KDM4E 2769/4885RAB9A 1056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.